Sramana Mitra: Interestingly, we’ve covered Destiny Solutions in 2013. Let me double-click down on a few different pieces of what you’ve told me so far. The one that I find the most interesting is in distributing our technology entrepreneurship courses. Over the last 15 years, we have developed one of the largest collection of early-stage
If you haven’t already, please study our Bootstrapping Course and Investor Introductions page. The theme of entrepreneurs building robust companies without outside capital continues in OnSIP CEO Mike Oeth’s story. Sramana Mitra: Let’s start at the beginning of your personal story. Where were you born, raised, and in what kind of circumstances? Mike Oeth: I was born in the MidWest,
Brian discusses a gigantic white space in continuing education that colleges and universities have left open. Modern Campus is trying to address this gap, among other things. Very interesting conversation. Sramana Mitra: Let’s start by introducing our audience to yourself as well as to Modern Campus.
Sramana Mitra: Tell me a bit about the company. Is it a funded company? Sridhar Iyengar: We’re venture-backed. We’re a Series A company. We’ve about 35 people in the company right now. Sramana Mitra: Where are you based? Sridhar Iyengar: We’re based in the Greater Boston area, but we have a distributed team.
This feature from Crunchbase News analyzes the funding trends in the gaming space. Venture-backed companies in the gaming space have raised a record $5.9 billion in funding so far in 2021. For this week’s posts, click on the paragraph links.
Entrepreneurs are invited to the 542nd FREE online 1Mby1M Mentoring Roundtable on Thursday, August 19, 2021, at 8 a.m. PDT/11 a.m. EDT/5 p.m. CEST/8:30 p.m. India IST. If you are a serious entrepreneur, register to “pitch” and sell your business idea. You’ll receive straightforward feedback, advice on next steps, and answers to any of your questions. Others
Sramana Mitra: What level of adoption are we talking about in LabOps as you call it. What is the pace of adoption in this world? Sridhar Iyengar: It really depends on the type of company that we’re working with. I mentioned synthetic biology. These companies were very early adopters because of the need of the
Sramana Mitra: Double-click down on MedTech labs. How exactly does your product play in that environment? Sridhar Iyengar: What we’ve seen in the last 10 years or so is that there’s been a tremendous acceleration of biotech and life science startups. Much more than the decade prior to that. One of the specialties is this